Related references
Note: Only part of the references are listed.A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
Margaret E. Ackerman et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
HIV-1 Replication in Langerhans and Interstitial Dendritic Cells Is Inhibited by Neutralizing and Fc-Mediated Inhibitory Antibodies
M. Peressin et al.
JOURNAL OF VIROLOGY (2011)
A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity
Joshua S. Klein et al.
AIDS (2010)
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody
Farrukh T. Awan et al.
BLOOD (2010)
A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
Pina M. Cardarelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances
Irene A. Abela et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Fc-Glycosylation Influences Fcγ Receptor Binding and Cell-Mediated Anti-HIV Activity of Monoclonal Antibody 2G12
Donald N. Forthal et al.
JOURNAL OF IMMUNOLOGY (2010)
In-Solution Virus Capture Assay Helps Deconstruct Heterogeneous Antibody Recognition of Human Immunodeficiency Virus Type 1
Daniel P. Leaman et al.
JOURNAL OF VIROLOGY (2010)
Antibodies to watch in 2010
Janice M. Reichert
MABS (2010)
Utilization of Immunoglobulin G Fc Receptors by Human Immunodeficiency Virus Type 1: a Specific Role for Antibodies against the Membrane-Proximal External Region of gp41
Lautaro G. Perez et al.
JOURNAL OF VIROLOGY (2009)
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
Ann J. Hessell et al.
NATURE MEDICINE (2009)
Glycosylation as a strategy to improve antibody-based therapeutics
Roy Jefferis
NATURE REVIEWS DRUG DISCOVERY (2009)
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Fc receptor-mediated antiviral antibodies
Donald N. Forthal et al.
CURRENT OPINION IN HIV AND AIDS (2009)
The Cat and Mouse of HIV-1 Antibody Escape
John R. Mascola
PLOS PATHOGENS (2009)
Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers
Ann J. Hessell et al.
PLOS PATHOGENS (2009)
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
John O. Richards et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
FcγRIIa genotype predicts progression of HIV infection
Donald N. Forthal et al.
JOURNAL OF IMMUNOLOGY (2007)
Optimizing engagement of the immune system by anti-timor antibodies: an engineer's perspective
John R. Desjarlais et al.
DRUG DISCOVERY TODAY (2007)
Fc receptor but not complement binding is important in antibody protection against HIV
Ann J. Hessell et al.
NATURE (2007)
Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate
Donald N. Forthal et al.
JOURNAL OF IMMUNOLOGY (2007)
Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells
Donald N. Forthal et al.
JOURNAL OF VIROLOGY (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
M Li et al.
JOURNAL OF VIROLOGY (2005)
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
A Trkola et al.
NATURE MEDICINE (2005)
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX® B/E prime-boost HIV-1 vaccine trial in Thailand
C Karnasuta et al.
VACCINE (2005)
Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251
VR Gómez-Román et al.
JOURNAL OF IMMUNOLOGY (2005)
CD107a as a functional marker for the identification of natural killer cell activity
G Alter et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120
RS Veazey et al.
NATURE MEDICINE (2003)
Fcγ receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro
AE Tebo et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2002)
Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS
ND Banks et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2002)
Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1
JR Mascola
VACCINE (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1
M Hezareh et al.
JOURNAL OF VIROLOGY (2001)
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
PWHI Parren et al.
JOURNAL OF VIROLOGY (2001)
Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design
EO Saphire et al.
SCIENCE (2001)
Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 the presence of natural-killer effector cells
DN Forthal et al.
JOURNAL OF VIROLOGY (2001)
Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections
VC Huber et al.
JOURNAL OF IMMUNOLOGY (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation
M Yagita et al.
LEUKEMIA (2000)
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
JR Mascola et al.
NATURE MEDICINE (2000)
Share Paper
